Therapeutic drug monitoring in patients with inflammatory bowel disease - Test2 - elhamkhani - TriplyDB

Therapeutic drug monitoring in patients with inflammatory bowel disease

Therapeutic drug monitoring in patients with inflammatory bowel disease

http://www.wikidata.org/entity/Q35140715

about

Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme.Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.Insights on the use of biosimilars in the treatment of inflammatory bowel disease.Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link.A Personalized Approach to Managing Inflammatory Bowel Disease.A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays.Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims.Role of Allopurinol in Optimizing Thiopurine Therapy in Patients with Autoimmune Hepatitis: A Review.Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis.Reactivation of Intestinal Inflammation Is Suppressed by Catestatin in a Murine Model of Colitis via M1 Macrophages and Not the Gut Microbiota.Impact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations: A Cohort Study.The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease.

P2860

Q33758469-C7EF0D79-F445-4E1E-8D7B-A2C75D2E4916 Q33865593-6A4567E5-8425-4027-A85B-CF2E64B3B35D Q35080243-37F09D19-A168-48C1-B39B-755DF32A6E48 Q36347059-9EB0C806-960F-41B8-84D5-0BECA3E4A23D Q37692717-FDACDD8C-6642-4A95-A05D-647629D3E125 Q38365049-C77710DB-256E-489E-B9AF-580DBB876125 Q38591244-12A59629-340B-4028-B6D5-4D481292E30A Q38735477-EFF137B0-48EF-48E0-8857-356109A03434 Q38826447-F76194FB-3F3A-48AA-936E-E999B247555F Q38833619-3495E2FB-17C3-4B02-9523-4ACBCF680886 Q38923616-31FDF319-E215-4A75-9647-D7F90A84E8ED Q39047005-CE4914A3-C5BA-4F99-8ADF-A3B2433826E2 Q39203629-75A9E0EA-2E77-4C25-9C47-A56C157C7E45 Q39251794-E29C1C5F-7461-4659-881C-E16321167F8A Q41487887-811B2D0A-75B0-481C-B9DE-2680CB92A5CC Q41493413-F7C487D1-8A88-4674-B991-15400715B927 Q42000636-BABEA2FC-424D-4EA3-A613-C63D03FBB941 Q43988900-4E4CACC5-88CF-4AA8-9AE9-53C60DB76F77 Q53772990-D7FDD0F8-8FD5-434D-8114-B67982324131

P2860

Therapeutic drug monitoring in patients with inflammatory bowel disease

http://www.wikidata.org/entity/Q35140715

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Therapeutic drug monitoring in patients with inflammatory bowel disease

@ast

Therapeutic drug monitoring in patients with inflammatory bowel disease

@en

type

label

Therapeutic drug monitoring in patients with inflammatory bowel disease

@ast

Therapeutic drug monitoring in patients with inflammatory bowel disease

@en

prefLabel

Therapeutic drug monitoring in patients with inflammatory bowel disease

@ast

Therapeutic drug monitoring in patients with inflammatory bowel disease

@en

P1433

Q35140715-DBD894C8-A942-4DC1-A4C8-04808E23104B

P1476

Q35140715-5F88435C-6181-4396-9710-2CC5015B0296

P2093

Q35140715-368F40F6-E13B-4939-A876-B68972972967

Q35140715-68F1B3C0-59FC-4C87-921B-7FC1C6584064

Q35140715-A0053657-BDB0-4F9F-8F03-6BE3929D6815

Q35140715-CE7A31DE-F4B3-4F27-8697-1386F36F3EE3

P2860

Q35140715-00EFF2FA-D42F-4031-8240-39964709A245

Q35140715-0FC1B5CD-5906-4EBC-8890-DED5F2B07387

Q35140715-10F789A4-94D7-4891-BB9C-E87673BCFD9D

Q35140715-14FACC91-2F81-48F6-A99F-128CA9DE70B1

Q35140715-1F8A34E0-C7D2-4430-92F2-0AE203BFE52C

Q35140715-24B1D058-7805-41D3-B5BE-15F03080557D

Q35140715-2542BE8C-7A96-4FF4-9A0C-F7BDD988853E

Q35140715-261ED84F-0B57-49B3-9EFF-67A28C66F1CC

Q35140715-2DCE44AC-5F54-457C-8D89-A10A1CE1B59D

Q35140715-306069E2-C243-4C8C-AC1D-8B2F93AC11BA

P304

Q35140715-7C489B2E-7D9C-4C8A-8417-DA18A87A94FC

P31

Q35140715-868EF58E-5091-4D3D-99E3-C813347096A7

P356

Q35140715-5E54E97A-AA1B-4443-9EE4-6A10893447A5

P407

Q35140715-B3BABE3B-4AC1-4E2E-BC36-3257B4412E19

P433

Q35140715-53EF1643-9CA0-4C10-A8C0-9D22351CCDBD

P478

Q35140715-DC9E3F40-19FE-4D5A-9B42-323B9AD89ABA

P50

Q35140715-1AE5CBDE-4006-4943-85D0-53340F551DC9

P577

Q35140715-FDD58A50-BDAB-4F54-9D85-6147DA14EC2E

P5875

Q35140715-F7B5C568-71EC-4BD2-9817-D2B221C69357

P698

Q35140715-B1F29F82-B6F3-40F7-8CCA-B6002B81A421

P921

Q35140715-73634F87-61D8-4E5D-94C3-CEAC5BD55C82

P932

Q35140715-3C1EFB8C-9DDC-47D7-A9DD-A2EFBFA9341D

P356

WJG.V20.I13.3475

P1433

World Journal of Gastroenterology

P1476

Therapeutic drug monitoring in patients with inflammatory bowel disease

@en

P2093

Amar R Deshpande

http://www.w3.org/2001/XMLSchema#string

Andres J Yarur

http://www.w3.org/2001/XMLSchema#string

Daniel A Sussman

http://www.w3.org/2001/XMLSchema#string

David H Kerman

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Infliximab for induction and maintenance therapy for ulcerative colitis

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.

Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

P304

3475-3484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V20.I13.3475

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261410234

http://www.w3.org/2001/XMLSchema#string

P698

24707130

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

3974514

http://www.w3.org/2001/XMLSchema#string